USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Set against a turbulent economic backdrop, a major fundraise from the life sciences division of Andera Partners shows there is still significant appetite for investment in the biotech sector. 10 October 2022
Yet another biotech start-up emerged from stealth this morning, indicating that there is no shortage of funding for companies with break-through technology. 6 October 2022
The US Government has expressed a vote of confidence in Vir Biotechnology, awarding the company a multi-year contract to advance the development of a full portfolio of innovative medicines. 5 October 2022
Cash rich Pfizer has completed its $11.6 billion acquisition of Biohaven Pharmaceutical, including its money-making calcitonin gene-related peptide (CGRP) programs. 5 October 2022
Japanese biotech Kyowa Kirin today announced it has launched its corporate venture capital (CVC) fund and invested in its first biotech start-up. 5 October 2022
The UK Chancellor of the Exchequer today announced at the mini-Budget the Long-Term Investment for Technology & Science (LIFTS) competition. 23 September 2022
Shares of US biotech Sesen Bio (Nasdaq: SESN) tumbled nearly 33% to $0.45 by close of trading yesterday, after it revealed a plan to merge with privately-held Carisma Therapeutics. 22 September 2022
Less than two months after Theravance Biopharma sold off rights to its share of royalties from parts of GSK’s respiratory franchise, the company announced an agreement to buy back equity from the British drugmaker. 20 September 2022
Founded by Yale professors Akiko Iwasaki and Anna Marie Pyle, RIGImmune has announced its launch, an acquisition and a financing all in a single day. 15 September 2022
Continuing this year’s trend of new venture capital-backed biotechs springing up, today sees the launch in the USA of Capstan Therapeutics, which says it is dedicated to developing and delivering precise in vivo cell engineering to patients, and has a bicoastal presence with operations in San Diego and Philadelphia. 14 September 2022
France-based SparingVision, a portfolio company of venture capital firm 4BIO Capital that is focussed on developing vision-saving treatments for ocular diseases, has raised 75 million euros in a Series B financing. 14 September 2022
Acelyrin, a late-stage clinical biopharma company focused on accelerating the delivery of transformative medicines in immunology, has announced a $300 million Series C financing to fund izokibep Phase III development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). 13 September 2022
California’s Arsenal Biosciences, a privately-held programmable cell therapy company engineering advanced CAR-T therapies for solid tumors, has closed a $220 million Series B financing. 7 September 2022
Nodus Oncology, a novel biotech company focused on developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets, has launched with seed funding from Cumulus Oncology and announced a partnership with the Lead Discovery Center (LDC). 6 September 2022
French clinical-stage biotech Abivax closed up 5.6% at 8.45 euros on Friday, after it announced the successful completion of an oversubscribed 49.2 million euros ($49.3 million) financing with high-quality US and European biotech specialist investors. 3 September 2022
Private equity firm Permira, in partnership with the Marcucci family and supported by their co-investors, have completed the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory (BPL). 1 September 2022
Arcturus Therapeutics, a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, has announced that it has obtained an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA). 1 September 2022
A biotechnology company aimed at creating a new class of medicines that precisely target disease biology, Vilya, has announced its launch with $50 million in committed Series A financing led by ARCH Venture Partners. 30 August 2022
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news